Evidence map›Paper›PMID 39656418›Full record

ArticleLa Radiologia medica2025

Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy.

Laetitia Saccenti, Nicole Varble, Tabea Borde, Andrew S Mikhail, Michael Kassin, Elliot Levy, Sheng Xu, Lindsey A Hazen, Ifechi Ukeh, Cyndi Vasco and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Laetitia SaccentiCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA. Laetitia.saccenti@nih.gov.ORCID http://orcid.org/0000-0002-9765-0039
Nicole VarbleCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Tabea BordeCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Andrew S MikhailCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Michael KassinCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Elliot LevyCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Sheng XuCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Lindsey A HazenCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Ifechi UkehCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Cyndi VascoCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Austin G DuffyGastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer, Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Changqing XieGastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer, Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Cecilia MongeGastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer, Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Donna MabryGastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer, Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Tim F GretenGastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer, Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Bradford J WoodCenter for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.

Funding

Société Française de Radiologie bourse de recherche Alain Rahmouni
6 · The paper itself

Abstract

purposeThe aim of this study was to assess the feasibility of quantifying morphologic changes in tumors during immunotherapy, as a reflection of response or survival. METHODS AND MATERIALS: A retrospective single-center analysis was performed in patients with unresectable liver cancer previously enrolled in clinical trials combining immunotherapy (tremelimumab ± durvalumab) and locoregional treatment (either ablation or transarterial chemoembolization). Conventional response (RECIST 1.1) was assessed at 6-month follow-up. For morphologic assessment, the largest target lesion was manually segmented on axial slices in two dimensions using contrast-enhanced CT. Solidity and circularity of tumors were calculated at baseline, 3-month follow-up, and at 6-months follow-up. Survival analysis was performed.

resultsFrom the 68 patients enrolled in clinical trials, 28 did not have target lesions separate from lesions treated by locoregional therapies, and 3 had no follow-up imaging. Thirty-seven patients (9 with biliary cancer and 28 with hepatocellular carcinoma) were included. Shape features and shape variation were not correlated with RECIST 1.1 status at 6-month follow-up. However, patients with low solidity tumors at 6-month follow-up showed poorer prognosis compared with patients with high solidity tumors at 6-month follow-up (p = 0.01). Solidity variation analysis confirmed that a decrease of tumor solidity at 6-month follow-up was associated with poorer prognosis (p = 0.01). No association was found between shape features at baseline or shape features at 3-month follow-up with overall survival.

conclusionEvolution and variation of tumor morphology during treatment may reflect or correlate with outcomes and contribute toward adapted response criteria.

Indexed as

Carcinoma, HepatocellularImmune Checkpoint InhibitorsLiver NeoplasmsTomography, X-Ray ComputedAgedAged, 80 and overChemoembolization, TherapeuticContrast MediaFeasibility StudiesFemaleHumansMaleMiddle AgedResponse Evaluation Criteria in Solid TumorsRetrospective StudiesTreatment OutcomeContrast MediaImmune Checkpoint InhibitorsFollow-up studiesImmunotherapyLiver neoplasmsResponse evaluation criteria in solid tumorsRetrospective studies

Identifiers

PMID39656418
PMCPMC11870906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.